Search

The article focuses on debates on access to medical products and disability bioethics that claims challenges and mentions appealing work on cognitive biases and theoretical work on problems of partial representation. Topics include optimism concerning sharing insights across experimental gaps, concerns raised by bioethics community on approaches weakening regulatory authority of U.S. Food & Drug Administration (FDA), and providing access on evidence to patients to interfere with trials.